<DOC>
	<DOC>NCT00644969</DOC>
	<brief_summary>Study will determine whether patients with schizophrenia or schizoaffective disorder can be helped to quit smoking safely while using varenicline and receiving smoking cessation counseling.</brief_summary>
	<brief_title>Smoking Cessation Study for Patients With Schizophrenia or Schizoaffective Disorder</brief_title>
	<detailed_description>This is a safety study.</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Varenicline</mesh_term>
	<criteria>Have a diagnosis (using the SCIDI/P at screening visit) of schizophrenia or schizoaffective disorder and judged to be stable (without hospitalization or acute exacerbation and functioning in society) on psychiatric treatment for at least the past 6 month. Current cigarette smokers (at least 15/day during the past year with no period of abstinence greater than 3 months in the past year) male or female, between the ages of 18 and 75 inclusive, who are motivated to stop smoking. Score 7 or higher on the Contemplation Ladder at the Screening, Week 1, and Baseline Visits. PANSS score &gt;70 at Screen or Baseline Visit. Subjects hospitalized within the past six months due to suicidal ideation or suicidal behavior or subjects considered to have serious suicidal ideation or suicidal behavior within the past six moth. Subjects having active suicidal ideation or behavior identified at Screen, Week 1, or Baseline Visit. Subjects taking Bupropion.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>